Erlotinib
GeneID | Mean_1 | Mean_3 | StDev_1 | StDev_3 | T-Statistic | p-value | Symbol | Description | |
---|---|---|---|---|---|---|---|---|---|
1 | 19 | 3.0 | 2.4 | 0.6 | 0.1 | -1.605 | 0.2442 | ABCA1 | ATP-binding cassette, sub-family A (ABC1), member 1 |
2 | 9429 | 2.8 | 6.4 | 0.5 | 0.3 | 11.391 | 0.0013 | ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) |
3 | 22985 | 10.0 | 10.2 | 0.1 | 0.1 | 2.723 | 0.0704 | ACIN1 | apoptotic chromatin condensation inducer 1 |
4 | 196 | 9.6 | 8.4 | 0.3 | 0.2 | -6.697 | 0.0045 | AHR | aryl hydrocarbon receptor |
5 | 231 | 2.7 | 5.8 | 0.3 | 0.1 | 16.078 | 0.0023 | AKR1B1 | aldo-keto reductase family 1, member B1 (aldose reductase) |
6 | 238 | 2.5 | 2.5 | 0.1 | 0.1 | 0.197 | 0.8553 | ALK | anaplastic lymphoma receptor tyrosine kinase |
7 | 367 | 12.4 | 12.2 | 0.1 | 0.2 | -1.364 | 0.2484 | AR | androgen receptor |
8 | 51761 | 2.8 | 4.2 | 0.2 | 0.2 | 8.068 | 0.0017 | ATP8A2 | ATPase, aminophospholipid transporter, class I, type 8A, member 2 |
9 | 9212 | 8.7 | 10.0 | 0.2 | 0.2 | 7.824 | 0.0014 | AURKB | aurora kinase B |
10 | 596 | 10.3 | 10.3 | 0.2 | 0.1 | 0.739 | 0.5268 | BCL2 | B-cell CLL/lymphoma 2 |
11 | 637 | 13.4 | 12.8 | 0.2 | 0.2 | -3.251 | 0.0322 | BID | BH3 interacting domain death agonist |
12 | 672 | 9.9 | 10.0 | 0.0 | 0.4 | 0.374 | 0.7433 | BRCA1 | breast cancer 1, early onset |
13 | 78996 | 9.9 | 11.0 | 0.2 | 0.1 | 9.881 | 0.0048 | C7orf49 | chromosome 7 open reading frame 49 |
14 | 836 | 8.2 | 8.0 | 0.3 | 0.2 | -1.211 | 0.3082 | CASP3 | caspase 3, apoptosis-related cysteine peptidase |
15 | 891 | 11.3 | 12.0 | 0.1 | 0.2 | 4.535 | 0.0280 | CCNB1 | cyclin B1 |
16 | 55536 | 9.5 | 8.5 | 0.2 | 0.1 | -6.800 | 0.0050 | CDCA7L | cell division cycle associated 7-like |
17 | 1000 | 3.2 | 3.2 | 0.4 | 0.1 | 0.188 | 0.8677 | CDH2 | cadherin 2, type 1, N-cadherin (neuronal) |
18 | 1029 | 6.0 | 6.5 | 0.4 | 0.0 | 2.330 | 0.1427 | CDKN2A | cyclin-dependent kinase inhibitor 2A |
19 | 81620 | 13.0 | 13.5 | 0.6 | 0.1 | 1.278 | 0.3241 | CDT1 | chromatin licensing and DNA replication factor 1 |
20 | 1084 | 2.6 | 3.0 | 0.3 | 0.7 | 0.902 | 0.4445 | CEACAM3 | carcinoembryonic antigen-related cell adhesion molecule 3 |
21 | 57396 | 8.6 | 9.0 | 0.3 | 0.3 | 1.354 | 0.2472 | CLK4 | CDC-like kinase 4 |
22 | 83548 | 10.1 | 10.1 | 0.0 | 0.2 | 0.698 | 0.5574 | COG3 | component of oligomeric golgi complex 3 |
23 | 1437 | 2.3 | 2.3 | 0.0 | 0.0 | 0.420 | 0.7020 | CSF2 | colony stimulating factor 2 (granulocyte-macrophage) |
24 | 114757 | 13.4 | 13.0 | 0.1 | 0.2 | -2.755 | 0.0760 | CYGB | cytoglobin |
25 | 1588 | 2.3 | 2.8 | 0.0 | 0.4 | 2.449 | 0.1329 | CYP19A1 | cytochrome P450, family 19, subfamily A, polypeptide 1 |
26 | 1558 | 2.2 | 2.8 | 0.0 | 0.6 | 1.477 | 0.2775 | CYP2C8 | cytochrome P450, family 2, subfamily C, polypeptide 8 |
27 | 4921 | 2.6 | 2.9 | 0.4 | 0.4 | 0.964 | 0.3899 | DDR2 | discoidin domain receptor tyrosine kinase 2 |
28 | 1666 | 11.2 | 10.5 | 0.2 | 0.3 | -3.384 | 0.0309 | DECR1 | 2,4-dienoyl CoA reductase 1, mitochondrial |
29 | 1950 | 2.3 | 2.4 | 0.0 | 0.1 | 1.016 | 0.4144 | EGF | epidermal growth factor |
30 | 1956 | 2.9 | 3.3 | 0.2 | 0.1 | 3.112 | 0.0782 | EGFR | epidermal growth factor receptor |
31 | 1973 | 14.2 | 14.4 | 0.0 | 0.1 | 4.859 | 0.0152 | EIF4A1 | eukaryotic translation initiation factor 4A1 |
32 | 1999 | 10.5 | 10.5 | 0.1 | 0.7 | 0.018 | 0.9875 | ELF3 | E74-like factor 3 (ets domain transcription factor, epithelial-specific ) |
33 | 27436 | 11.9 | 12.3 | 0.1 | 0.0 | 4.717 | 0.0311 | EML4 | echinoderm microtubule associated protein like 4 |
34 | 2048 | 5.7 | 5.8 | 0.3 | 0.2 | 0.700 | 0.5288 | EPHB2 | EPH receptor B2 |
35 | 2064 | 9.7 | 9.0 | 0.4 | 0.3 | -2.344 | 0.0865 | ERBB2 | erb-b2 receptor tyrosine kinase 2 |
36 | 2065 | 9.6 | 9.3 | 0.1 | 0.2 | -2.412 | 0.0886 | ERBB3 | erb-b2 receptor tyrosine kinase 3 |
37 | 2066 | 7.9 | 5.6 | 0.2 | 0.3 | -11.036 | 0.0005 | ERBB4 | erb-b2 receptor tyrosine kinase 4 |
38 | 2099 | 11.4 | 9.4 | 0.1 | 0.2 | -16.793 | 0.0003 | ESR1 | estrogen receptor 1 |
39 | 2321 | 2.4 | 2.5 | 0.1 | 0.1 | 0.409 | 0.7102 | FLT1 | fms-related tyrosine kinase 1 |
40 | 2580 | 9.3 | 8.8 | 0.1 | 0.2 | -3.432 | 0.0445 | GAK | cyclin G associated kinase |
41 | 2996 | 2.3 | 2.3 | 0.0 | 0.0 | -0.435 | 0.6861 | GYPE | glycophorin E (MNS blood group) |
42 | 3014 | 13.3 | 13.7 | 0.1 | 0.2 | 2.466 | 0.0809 | H2AFX | H2A histone family, member X |
43 | 3265 | 10.7 | 10.7 | 0.2 | 0.4 | -0.278 | 0.8001 | HRAS | Harvey rat sarcoma viral oncogene homolog |
44 | 3480 | 12.9 | 12.8 | 0.3 | 0.2 | -0.296 | 0.7828 | IGF1R | insulin-like growth factor 1 receptor |
45 | 3484 | 2.4 | 2.2 | 0.2 | 0.0 | -0.937 | 0.4466 | IGFBP1 | insulin-like growth factor binding protein 1 |
46 | 3569 | 2.3 | 2.3 | 0.0 | 0.0 | -0.440 | 0.6964 | IL6 | interleukin 6 |
47 | 3717 | 7.8 | 9.0 | 0.2 | 0.4 | 5.183 | 0.0187 | JAK2 | Janus kinase 2 |
48 | 3791 | 2.4 | 2.3 | 0.0 | 0.1 | -0.496 | 0.6472 | KDR | kinase insert domain receptor |
49 | 57650 | 2.6 | 2.7 | 0.2 | 0.3 | 0.448 | 0.6816 | KIAA1524 | KIAA1524 |
50 | 3815 | 2.3 | 2.3 | 0.1 | 0.0 | -0.184 | 0.8629 | KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
51 | 3880 | 18.2 | 18.4 | 0.1 | 0.0 | 3.350 | 0.0508 | KRT19 | keratin 19, type I |
52 | 3854 | 2.3 | 4.2 | 0.1 | 1.2 | 2.630 | 0.1181 | KRT6B | keratin 6B, type II |
53 | 3939 | 13.5 | 13.5 | 0.2 | 0.3 | 0.040 | 0.9697 | LDHA | lactate dehydrogenase A |
54 | 4214 | 11.6 | 11.1 | 0.1 | 0.1 | -4.921 | 0.0154 | MAP3K1 | mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase |
55 | 5595 | 8.9 | 9.2 | 0.3 | 0.1 | 1.920 | 0.1525 | MAPK3 | mitogen-activated protein kinase 3 |
56 | 4233 | 9.9 | 11.6 | 0.1 | 0.1 | 28.016 | 0.0001 | MET | MET proto-oncogene, receptor tyrosine kinase |
57 | 4318 | 10.6 | 9.4 | 0.1 | 0.3 | -6.225 | 0.0138 | MMP9 | matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) |
58 | 2475 | 8.9 | 9.1 | 0.0 | 0.1 | 3.319 | 0.0559 | MTOR | mechanistic target of rapamycin (serine/threonine kinase) |
59 | 4609 | 8.9 | 8.0 | 0.4 | 0.6 | -2.174 | 0.1053 | MYC | v-myc avian myelocytomatosis viral oncogene homolog |
60 | 4691 | 15.3 | 15.0 | 0.0 | 0.3 | -1.484 | 0.2676 | NCL | nucleolin |
61 | 4780 | 3.0 | 4.4 | 0.8 | 2.1 | 1.080 | 0.3704 | NFE2L2 | nuclear factor, erythroid 2-like 2 |
62 | 2908 | 9.6 | 12.1 | 0.2 | 0.2 | 12.739 | 0.0002 | NR3C1 | nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
63 | 3084 | 2.6 | 2.6 | 0.2 | 0.1 | -0.234 | 0.8278 | NRG1 | neuregulin 1 |
64 | 10133 | 7.3 | 7.4 | 0.2 | 0.1 | 1.199 | 0.3034 | OPTN | optineurin |
65 | 10038 | 11.1 | 11.8 | 0.3 | 0.3 | 3.112 | 0.0358 | PARP2 | poly (ADP-ribose) polymerase 2 |
66 | 5077 | 2.9 | 3.2 | 0.4 | 0.3 | 1.051 | 0.3563 | PAX3 | paired box 3 |
67 | 5111 | 12.0 | 13.1 | 0.2 | 0.4 | 4.276 | 0.0250 | PCNA | proliferating cell nuclear antigen |
68 | 255738 | 2.3 | 2.4 | 0.0 | 0.2 | 1.182 | 0.3583 | PCSK9 | proprotein convertase subtilisin/kexin type 9 |
69 | 283871 | 9.2 | 9.5 | 0.2 | 0.4 | 1.469 | 0.2460 | PGP | phosphoglycolate phosphatase |
70 | 5241 | 10.2 | 11.5 | 0.2 | 0.1 | 9.929 | 0.0013 | PGR | progesterone receptor |
71 | 5293 | 3.8 | 3.0 | 0.6 | 0.2 | -2.016 | 0.1586 | PIK3CD | phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
72 | 55558 | 11.7 | 11.8 | 0.2 | 0.2 | 0.458 | 0.6717 | PLXNA3 | plexin A3 |
73 | 5468 | 2.3 | 4.0 | 0.0 | 0.5 | 5.713 | 0.0291 | PPARG | peroxisome proliferator-activated receptor gamma |
74 | 5728 | 10.1 | 9.8 | 0.0 | 0.1 | -3.208 | 0.0714 | PTEN | phosphatase and tensin homolog |
75 | 2185 | 9.1 | 8.2 | 0.0 | 0.4 | -4.284 | 0.0472 | PTK2B | protein tyrosine kinase 2 beta |
76 | 5923 | 3.0 | 2.3 | 1.2 | 0.1 | -0.992 | 0.4255 | RASGRF1 | Ras protein-specific guanine nucleotide-releasing factor 1 |
77 | 6098 | 4.4 | 2.6 | 0.3 | 0.5 | -5.609 | 0.0063 | ROS1 | ROS proto-oncogene 1 , receptor tyrosine kinase |
78 | 6185 | 12.8 | 13.3 | 0.1 | 0.1 | 6.250 | 0.0058 | RPN2 | ribophorin II |
79 | 677775 | 7.5 | 7.5 | 0.1 | 0.1 | -0.090 | 0.9327 | SCARNA5 | small Cajal body-specific RNA 5 |
80 | 9644 | 3.4 | 2.9 | 0.4 | 0.4 | -1.640 | 0.1765 | SH3PXD2A | SH3 and PX domains 2A |
81 | 6581 | 2.4 | 2.4 | 0.0 | 0.1 | 0.029 | 0.9782 | SLC22A3 | solute carrier family 22 (organic cation transporter), member 3 |
82 | 9748 | 9.5 | 9.6 | 0.1 | 0.2 | 0.590 | 0.6044 | SLK | STE20-like kinase |
83 | 9126 | 11.5 | 11.9 | 0.1 | 0.2 | 2.424 | 0.0778 | SMC3 | structural maintenance of chromosomes 3 |
84 | 23583 | 9.9 | 9.9 | 0.1 | 0.0 | 0.634 | 0.5814 | SMUG1 | single-strand-selective monofunctional uracil-DNA glycosylase 1 |
85 | 6714 | 6.5 | 7.6 | 0.1 | 0.1 | 13.718 | 0.0002 | SRC | SRC proto-oncogene, non-receptor tyrosine kinase |
86 | 6774 | 7.9 | 7.4 | 0.2 | 0.1 | -4.219 | 0.0140 | STAT3 | signal transducer and activator of transcription 3 (acute-phase response factor) |
87 | 55775 | 11.6 | 11.9 | 0.0 | 0.1 | 4.751 | 0.0210 | TDP1 | tyrosyl-DNA phosphodiesterase 1 |
88 | 7030 | 9.5 | 9.5 | 0.1 | 0.1 | 0.636 | 0.5634 | TFE3 | transcription factor binding to IGHM enhancer 3 |
89 | 7157 | 7.9 | 7.4 | 0.3 | 0.5 | -1.440 | 0.2378 | TP53 | tumor protein p53 |
90 | 7248 | 7.0 | 6.6 | 0.5 | 0.0 | -1.693 | 0.2299 | TSC1 | tuberous sclerosis 1 |
91 | 7298 | 12.8 | 13.6 | 0.0 | 0.4 | 3.424 | 0.0753 | TYMS | thymidylate synthetase |
92 | 7422 | 8.5 | 8.5 | 0.5 | 0.2 | 0.009 | 0.9937 | VEGFA | vascular endothelial growth factor A |
93 | 7431 | 4.9 | 6.7 | 0.5 | 0.1 | 6.548 | 0.0153 | VIM | vimentin |
94 | 7525 | 9.9 | 9.8 | 0.1 | 0.1 | -0.554 | 0.6091 | YES1 | YES proto-oncogene 1, Src family tyrosine kinase |
95 | 22882 | 9.6 | 10.2 | 0.1 | 0.3 | 3.424 | 0.0581 | ZHX2 | zinc fingers and homeoboxes 2 |